SEPN — Septerna, Inc. Stock Price, Chart & AI Report

Positive Mar 1, 2026 • 14:45 UTC GlobeNewswire Inc. • Na

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

Septerna announced positive Phase 1 results for SEP-631, an oral MRGPRX2 negative allosteric modulator for treating mast cell-driven diseases. The drug demonstrated robust, dose-dependent inhibition of icatibant-induced skin wheal formation with complete inhibition at 10 mg once-daily, was well-tolerated with an adverse event profile comparable to placebo, and showed a pharmacokinetic profile supporting once-daily dosing. The company plans to initiate Phase 2b development in chronic spontaneous urticaria in the second half of 2026.

SEPN SEP-631 MRGPRX2 Phase 1 clinical trial chronic spontaneous urticaria mast cell activation negative allosteric modulator oral small molecule

Sentiment note

Positive Phase 1 data showing robust dose-dependent efficacy, excellent tolerability comparable to placebo, and favorable pharmacokinetics supporting once-daily dosing. Clear clinical proof-of-mechanism for MRGPRX2 pathway inhibition and advancement to Phase 2b in CSU with additional indications being evaluated positions the company favorably for future development.

Positive Nov 25, 2025 • 13:00 UTC GlobeNewswire Inc. • Renee Leck/Carly Scaduto

Septerna to Participate in 8th Annual Evercore Healthcare Conference

Septerna, a clinical-stage biotechnology company specializing in GPCR drug discovery, will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, presenting via live webcast.

SEPN biotechnology GPCR drug discovery healthcare conference webcast

Sentiment note

Company is showcasing ongoing clinical trials, highlighting progress in drug development (SEP-479 and SEP-631), and maintaining a robust financial position of $561.6 million

Positive May 23, 2025 • 13:29 UTC Investing.com • Marketbeat.Com

Analysts Think These Stocks Could More Than Double in Value

Analysts believe three healthcare stocks - Septerna Inc, Intellia Therapeutics, and Novavax - have the potential to at least double in price, although they carry varying levels of risk.

SEPN NTLA NVAX stocks healthcare biotechnology drug development growth potential

Sentiment note

Septerna recently secured a major partnership with Novo Nordisk worth over $2 billion, which should provide substantial flexibility for its research and development operations. Analysts have a consensus price target of $27, roughly triple the current price.

Positive May 15, 2025 • 12:29 UTC Investing.com • Marketbeat.Com

Is It Time to Buy the Dip in Novo Nordisk Stock?

Novo Nordisk stock is down nearly 50% in 2025 despite a double beat in its quarterly earnings. Analysts believe the stock has significant upside, but factors like increased competition and a new executive order on drug pricing could weigh on the stock in the short term.

NVO LLY CVS SEPN Novo Nordisk Eli Lilly CVS Health Septerna

Sentiment note

Novo Nordisk's $2.2 billion deal with Septerna to co-develop new oral small-molecule therapies, including one targeting obesity, is seen as a positive move to address the increased competition.

Negative Feb 19, 2025 • 23:00 UTC GlobeNewswire Inc. • N/A

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

Kirby McInerney LLP is investigating potential claims against Septerna, Inc. (NASDAQ:SEPN) after the company announced the discontinuation of a clinical trial for its hypoparathyroidism treatment due to unexpected severe cases of elevated unconjugated bilirubin.

SEPN Septerna hypoparathyroidism clinical trial

Sentiment note

The company announced the discontinuation of a clinical trial for its hypoparathyroidism treatment due to unexpected severe adverse events, which led to a significant decline in the company's stock price.

Positive Dec 18, 2024 • 13:00 UTC GlobeNewswire Inc. • N/A

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Septerna, a clinical-stage biotechnology company, announced that its CEO will present at the upcoming J.P. Morgan Healthcare Conference. The company is pioneering a new era of GPCR-targeted drug discovery using its proprietary Native Complex Platform.

SEPN Septerna GPCR drug discovery J.P. Morgan Healthcare Conference

Sentiment note

The article highlights Septerna's progress as a clinical-stage biotechnology company, its innovative GPCR-targeted drug discovery platform, and its upcoming presentation at a major industry conference, which suggests the company is making advancements in its business.

Positive Nov 20, 2024 • 12:00 UTC GlobeNewswire Inc. • N/A

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Septerna, a clinical-stage biotechnology company, reported financial results for Q3 2024 and provided an update on its GPCR drug discovery pipeline. The company's lead program, SEP-786, is in a Phase 1 trial for hypoparathyroidism, with data expected in mid-2025. Septerna also has several other GPCR-targeted programs in development for endocrinology, immunology, inflammation, and metabolic diseases.

SEPN GPCR hypoparathyroidism endocrinology immunology inflammation metabolic diseases

Sentiment note

The article highlights Septerna's progress in advancing its GPCR drug discovery pipeline, including the initiation of a Phase 1 trial for its lead program SEP-786 and the development of several other GPCR-targeted programs. The company also recently completed a successful IPO, raising $302.6 million in net proceeds, which is expected to support its operations into the second half of 2027.